Request Demo

Last update 08 May 2025

CA1

Last update 08 May 2025

Basic Info

Synonyms

CA-I, CA1, CAB

+ [7]

Introduction

Catalyzes the reversible hydration of carbon dioxide (PubMed:10550681, PubMed:16506782, PubMed:16686544, PubMed:16807956, PubMed:17127057, PubMed:17314045, PubMed:17407288, PubMed:18618712, PubMed:19186056, PubMed:19206230). Can hydrate cyanamide to urea (PubMed:10550681).

Drugs associated with CA1

Methocarbamol

Target

CA1

Mechanism

CA1 inhibitors

Active Org.

Hikma Pharmaceuticals USA, Inc. [+3]

Originator Org.

Endo International Plc

Active Indication

Musculoskeletal Pain

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date16 Jul 1957

Meloxicam/Methocarbamol

Target

CA1 x COX-2

Mechanism

CA1 inhibitors [+1]

Active Org.

Teva Pharmaceutical Industries Ltd.

Originator Org.-

Active Indication

Arthritis [+5]

Inactive Indication

Breakthrough Pain [+1]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Loxoprofen Sodium/Methocarbamol

Target

CA1 x COXs

Mechanism

CA1 inhibitors [+1]

Active Org.

C.H. Boehringer Sohn AG & Co. KG

Originator Org.

C.H. Boehringer Sohn AG & Co. KG

Active Indication

Pain

Inactive Indication-

Drug Highest PhasePhase 3

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with CA1

CTR20242833

/ CompletedNot Applicable

评估受试制剂美索巴莫片（规格：500 mg）与参比制剂美索巴莫片（规格：500 mg）在健康成年受试者餐后状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性研究

[Translation] A single-center, open-label, randomized, single-dose, two-period, two-sequence, crossover bioequivalence study to evaluate the bioequivalence of the test preparation, methocarbamol tablets (strength: 500 mg), and the reference preparation, methocarbamol tablets (strength: 500 mg) in healthy adult subjects in the fed state

主要研究目的：研究餐后状态下单次口服受试制剂美索巴莫片（规格：500 mg，石家庄四药有限公司生产）与参比制剂美索巴莫片（规格：500 mg，Granules India Ltd生产）在健康受试者体内的药代动力学，评价餐后状态下口服两种制剂的生物等效性。次要研究目的：评估受试制剂美索巴莫片（规格：500 mg）和参比制剂美索巴莫片（规格：500 mg）在健康受试者中的安全性。

[Translation]

The main purpose of the study is to study the pharmacokinetics of the test preparation methocarbamol tablets (specification: 500 mg, produced by Shijiazhuang Siyao Co., Ltd.) and the reference preparation methocarbamol tablets (specification: 500 mg, produced by Granules India Ltd) in healthy subjects after a single oral administration in the fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fed state. The secondary purpose of the study is to evaluate the safety of the test preparation methocarbamol tablets (specification: 500 mg) and the reference preparation methocarbamol tablets (specification: 500 mg) in healthy subjects.

Start Date26 Aug 2024

Sponsor / Collaborator

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

CTR20242834

/ CompletedNot Applicable

评估受试制剂美索巴莫片（规格：500 mg）与参比制剂美索巴莫片（规格：500 mg）在健康成年受试者空腹状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性研究

[Translation] A single-center, open-label, randomized, single-dose, two-period, two-sequence, crossover bioequivalence study to evaluate the test preparation methocarbamol tablets (strength: 500 mg) and the reference preparation methocarbamol tablets (strength: 500 mg) in healthy adult subjects under fasting state

主要研究目的：研究空腹状态下单次口服受试制剂美索巴莫片（规格：500 mg，石家庄四药有限公司生产）与参比制剂美索巴莫片（规格：500 mg，Granules India Ltd生产）在健康受试者体内的药代动力学，评价空腹状态下口服两种制剂的生物等效性。次要研究目的：评估受试制剂美索巴莫片（规格：500 mg）和参比制剂美索巴莫片（规格：500 mg）在健康受试者中的安全性。

[Translation]

The main purpose of the study is to study the pharmacokinetics of the test preparation methocarbamol tablets (specification: 500 mg, produced by Shijiazhuang Siyao Co., Ltd.) and the reference preparation methocarbamol tablets (specification: 500 mg, produced by Granules India Ltd) in healthy subjects after a single oral administration under fasting conditions, and to evaluate the bioequivalence of the two preparations when taken orally under fasting conditions. The secondary purpose of the study is to evaluate the safety of the test preparation methocarbamol tablets (specification: 500 mg) and the reference preparation methocarbamol tablets (specification: 500 mg) in healthy subjects.

Start Date24 Aug 2024

Sponsor / Collaborator

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

EUCTR2022-000788-30-PL

/ Not yet recruitingPhase 4

Evaluation of the effectiveness of Methocarbamol in the treatment ofspasticity in people with spinal cord injury.

Start Date13 Apr 2023

Sponsor / Collaborator-

100 Clinical Results associated with CA1

100 Translational Medicine associated with CA1

0 Patents (Medical) associated with CA1

1,794

Literatures (Medical) associated with CA1

01 Aug 2025·Journal of Colloid and Interface Science

Calcium single atom catalyst with unusual activity and stability for the synthesis of dimethyl carbonate

Article

Author: Sun, Lin-Bing ; Peng, Song-Song ; Shao, Xiang-Bin ; Liu, Sai ; Tan, Peng ; Song, Xing-Ru ; Xing, Zhi-Wei ; Xu, Hao-Cheng

Solid base catalysts with strong basicity are highly desirable for various reactions because of their minimal corrosion, ease of separation, and environmental sustainability. Nevertheless, their broader application is hindered by issues including mediocre activity and poor stability. Herein, aiming at enhancing the catalytic performance and stability of conventional solid bases, we designed and fabricated calcium (Ca) single-atom solid bases on zeolite imidazolate framework (ZIF-8) derived N-doped carbon (NPC) with Ca-N₄ motifs as the active center for transesterification of methanol and ethylene carbonate. Benefiting from the highly dispersed Ca atoms and strong metal-substrate interaction, the Ca₁/NPC exhibits unusual activity (35.1 %) and stability (5 cycles without obvious deactivation) in transesterification to produce dimethyl carbonate (DMC), which significantly surpasses its analogue CaO/NPC and multiple reported alkali/alkaline-earth metal derived solid base catalysts with superbasicity. Moreover, the turnover frequency (TOF) is 123.0 h^-1 on Ca₁/NPC, significantly surpassing that of traditional Ca-based counterparts (6.4 and 8.6 h^-1) and even outperforming typical alkali metal derived catalysts with superbasicity (6.8-36.2 h^-1). This study not only offers an advanced Ca-N-based catalyst for transesterification but also provides direction for fabricating single-atom solid strong bases for a variety of heterogeneous catalytic process.

01 Jun 2025·Atherosclerosis Plus

ApoE [−/−] CA1-overexpressing knock-in mice aggravated atherosclerosis by increasing M1 macrophages

Article

Author: Wang, Changyuan ; Fang, Kehua ; Zhou, Hongji ; Chang, Xiaotian ; Song, Yu ; Zong, Jinbao

BackgroundCarbonic anhydrase I (CA1) has been reported to be a diagnostic and therapeutic target for atherosclerosis (AS). This study aimed to verify the essential role of CA1 in AS progression in CA1-overexpressing mice.MethodsA ApoE [-/-] CA1-overexpressing knock-in mouse model was constructed via CRISPR/Cas9-mediated genome engineering. AS was then induced in these transgenic mice via the administration of a high-fat diet, and a second group simultaneously received treatment with methazolamide (MTZ), a carbonic anhydrase inhibitor.ResultsCompared with ApoE [-/-] mice without CA1 overexpression, CA1-overexpressing mice had a greater average body weight, regardless of whether their treatment with MTZ or their AS induction status. Sudan IV, hematoxylin and eosin and Oil Red O staining revealed more plaques and fat deposits in the cardiac aortas of CA1-overexpressing mice than in those of ordinary ApoE-/- mice when AS was induced. Moreover, the atherogenic index; low-density lipoprotein, total cholesterol and triglyceride levels were significantly elevated, and high-density lipoprotein levels were declined in the peripheral blood of CA1-overexpressing mice than in that of ordinary ApoE [-/-] mice, regardless of whether these animals were induced to AS. Immunohistochemistry, Von Kossa staining and fluorescence immunohistochemistry revealed increases in CA1 expression, calcium deposition and M1 macrophages in the aortic tissues of CA1-overexpressing mice with AS. MTZ treatment significantly suppressed AS pathologies in the above experiments.ConclusionThese findings revealed aggravated AS in ApoE [-/-] CA1-overexpressing mice and suggest that CA1 aggravates AS by increasing M1-type macrophages, a proinflammatory macrophage subtype.

12 May 2025·International Journal of Phytoremediation

Calcium–magnesium synergy in reducing cadmium bioavailability and uptake in rice plants

Article

Author: Si, Mengying ; Huang, Peicheng ; Xu, Hao ; Yang, Zhihui ; Tang, Chongjian ; Wang, Qiming ; Arinzechi, Chukwuma ; Ping, Yang ; Li, Qingzhu

The synergistic application of calcium (Ca) and magnesium (Mg) was investigated to mitigate cadmium (Cd) uptake and translocation in rice grown in Cd-contaminated soil. A pot experiment was conducted using different Ca:Mg molar ratios (Ca1:Mg2, Ca2:Mg1, and Ca1:Mg1) to evaluate their effect on Cd uptake. The results showed that the Ca1:Mg1 treatment achieved the highest reduction in grain Cd content (54.7%, p < 0.05), followed by Ca2:Mg1 (47.6%), and Ca1:Mg2 (40.7%), all below China's National Food Safety Standard (0.2 mg kg^-1). Significant reductions were also observed in roots, stems, and leaves (p < 0.05). Ca1:Mg1 minimized Cd translocation by decreasing stem-to-grain transfer by 61.0% and xylem sap Cd by 50.1% (p < 0.05). It also reduced mobile Cd fractions in roots (F_E from 25% to 18%, F_Di from 44% to 37%) and increased DCB-extractable Fe (DCB-Fe) on roots, enhancing Cd immobilization. Ca:Mg treatments raised soil pH by 23.6-25.7% (p < 0.05), shifting Cd from bioavailable forms (F_EX reduced by 9.3%, F_CB by 17.8%) to more stable forms (F_Fe/Mn increased by 15.5%, F_OM by 1.9%). Strong negative correlations (p < 0.05, 0.01) between soil pH, DCB-Fe, Ca, Mg_TF, F_Fe/Mn, and grain Cd indicating their effect in reducing Cd uptake.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

CA1

Basic Info

Related

Analysis